Featured Research

from universities, journals, and other organizations

Potential Therapeutic Strategy For Hepatic Failure

Date:
March 30, 2009
Source:
World Journal of Gastroenterology
Summary:
A research group from China evaluated the effect of intrahepatic transplantation of hepatic oval cells (HOC) on fulminant hepatic failure (FHF) in rats. They found that HOC transplantation could improve the liver function and increase the survival rate of recipients.

Fulminant hepatic failure is a serious clinical disease and may threaten the life of patients. However, because of the damage of mass liver cells, the organ function is often irreversible due to the liver cell degeneration, swelling, or apoptosis. Thus, to supply new sources of functional liver cells is a valuable choice for these patients.

Related Articles


A research team led by Dr. Yi -Jun Wang from Tianjin Medical University of China addressed this issue. In their study, HOC from rats were labeled with green fluocescent protein (GFP) or 5,6-carboxyfluorescein diacetate succinmidyl ester (CFDASE). Cell fluorescence was observed under fluorescent microscope at 6, 24, 48 and 72 h after labeling. CFDASE labeled HOC (5 106 cells each rat) were injected into livers of rats with FHF induced by D-galactosamine. Serum albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBil) levels were measured at different time points. Liver function of rats was examined on days 3, 7, 14 and 21 after HOC transplantation.

They found that the positive rate of GFP and CFDA-SE labeled HOC was 10% and 90%, respectively, with no significant change in cell viabilities. The survival rate was higher in HOC transplantation group than in control group, especially 48 (9/15 vs 6/15) and 72 h (9/15 vs 4/15) after HOC transplantation. The serum ALT, AST and TBil levels were decreased while the serum Alb level was increased after HOC transplantation. Fluorescence became faded and diffused in liver tissues, suggesting that proliferation and differentiation occur in transplanted HOC. The results of this study suggest that the presence of single nucleotide polymorphisms (SNPs) in certain positions had direct effect on the response of HCV patients to interferon therapy. Taking into consideration the positions of these mutations, different real-time PCR or other assays can be developed for detection of the SNPs to allow the prediction of the response to interferon therapy as a step for identification of patients who are more likely to respond to therapy.

Their result indicated that CFDA-SE is superior to GFP in labeling HOC, although fluorescence intensity is decreased progressively with cell division. HOC transplantation could improve the liver function and increase the survival rate of recipients.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wu et al. Intrahepatic transplantation of hepatic oval cells for fulminant hepatic failure in rats. World Journal of Gastroenterology, 2009; 15 (12): 1506 DOI: 10.3748/wjg.15.1506

Cite This Page:

World Journal of Gastroenterology. "Potential Therapeutic Strategy For Hepatic Failure." ScienceDaily. ScienceDaily, 30 March 2009. <www.sciencedaily.com/releases/2009/03/090330123217.htm>.
World Journal of Gastroenterology. (2009, March 30). Potential Therapeutic Strategy For Hepatic Failure. ScienceDaily. Retrieved April 21, 2015 from www.sciencedaily.com/releases/2009/03/090330123217.htm
World Journal of Gastroenterology. "Potential Therapeutic Strategy For Hepatic Failure." ScienceDaily. www.sciencedaily.com/releases/2009/03/090330123217.htm (accessed April 21, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, April 21, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Teva Offers $40 Billion for Mylan

Teva Offers $40 Billion for Mylan

Reuters - Business Video Online (Apr. 21, 2015) Generic drugmaker Teva Pharmaceutical is offering $82 a share, or $40 billion, for its smaller rival Mylan, in an alternative to Mylan&apos;s deal to buy Perrigo. Bobbi Rebell reports. Video provided by Reuters
Powered by NewsLook.com
Blue Bell Recalls All Products

Blue Bell Recalls All Products

AP (Apr. 21, 2015) Blue Bell Creameries voluntary recalled for all of its products after two samples of chocolate chip cookie dough ice cream tested positive for listeria, a potentially deadly bacteria. Blue Bell&apos;s President and CEO issued a video statement. (April 21) Video provided by AP
Powered by NewsLook.com
Yemen Doctors at Breaking Point

Yemen Doctors at Breaking Point

Reuters - News Video Online (Apr. 21, 2015) A Sanaa hospital struggles to cope with the high number of casualties with severe injuries, after an air strike left at least 25 dead and hundreds wounded. Deborah Lutterbeck reports. Video provided by Reuters
Powered by NewsLook.com
'Tutu Tuesdays' Brighten Faces at Kids' Hospital

'Tutu Tuesdays' Brighten Faces at Kids' Hospital

AP (Apr. 21, 2015) Doctors and nurses have started wearing ballet tutus every Tuesday to cheer up young hospital patients at a Florida hospital. It started with a request made by a nervous patient -- now, almost the entire staff is wearing the tutus. (April 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins